Critical analysis of the concept of adult attention-deficit hyperactivity disorder

Psychiatrist

Volumn 35, Issue 9, 2011, Pages 334-338

  Moncrieff, Joanna ^a   Timimi, Sami ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LINCOLNSHIRE PARTNERSHIP NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE;

ARTICLE; ATTENTION DEFICIT DISORDER; CHILDHOOD DISEASE; DRUG INDUSTRY; HUMAN; MENTAL DISEASE;

EID: 80052390166     PISSN: 17583209     EISSN: 17583217     Source Type: Journal    
DOI: 10.1192/pb.bp.110.033423     Document Type: Article

References (53)

1. Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006; 163: 716-23.
2. Simon V, Czobor P, Bálint S, Mészáros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: metaanalysis. Br J Psychiatry 2009; 194: 204-11.
3. Conrad P, Potter D. From hyperactive children to ADHD adults: observations on the expansion of medical categories. Soc Prob 2000; 47: 559-82.
4. National Institute for Health and Clinical Excellence. Attention Deficit Hyperactivity Disorder: Diagnosis and Management of ADHD in Children, Young People and Adults (National Clinical Practice Guideline Number 72). NICE, 2008.
5. American Psychiatric Association. Proposed Revisions to the Diagnostic and Statistical Manual. APA, 2010.
6. Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Brugue M, Carpentier PJ, et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network. Adult ADHD. BMC Psychiatry 2010; 10: 67.
7. Wong IC, Asherson P, Bilbow A, Clifford S, Coghill D, DeSoysa R, et al. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY) - a pharmacoepidemiological and qualitative study. Health Technol Assess 2009; 13: iii-xi, 1-120.
8. Taylor N, Fauset A, Harpin V. Young adults with ADHD: an analysis of their service needs on transfer to adult services. Arch Dis Child 2010; 95: 513-7.
9. Shaffer D. Attention deficit hyperactivity disorder in adults. Am J Psychiatry 1994; 151: 633-8.
10. Arria AM, Caldeira KM, O'Grady KE, Vincent KB, Johnson EP,Wish ED. Nonmedical use of prescription stimulants among college students: associations with attention-deficit-hyperactivity disorder and polydrug use. Pharmacotherapy 2008; 28: 156-69.
11. NHS Information Centre. Prescription Cost Analysis, England - 2009. The Information Centre, 2010.
12. Castle L, Aubert RE, Verbrugge RR, Khalid M, Epstein RS. Trends in medication treatment for ADHD. J Atten Disord 2007; 10: 335-42.
13. Lead Discovery. Adult ADHD-Therapeutic Opportunities. Lead Discovery, 2004 (http://www.leaddiscovery.co.uk/reports/813/Adult-ADHD-Therapeutic- Opportunities).
14. Food and Drug Administration. FDA warning letter RE: NDA 21-411, Strattera (atomoxetine HCl). FDA, 2005 (http://pharmcast.com/WarningLetters/ Yr2005/Jun2005/EliLilly0605.htm).
15. Food and Drug Administration.Warning letter RE: NDA 21-411 Strattera (atomoxetine HCl). FDA, 2008 (http://www.fda.gov/downloads/Drugs/ GuidanceComplianceregulatoryInformation/EnforcementActivityFDA/ WarningLettersandNoticeofViolationLettersto PharmaceuticalCompanies/ucm054007. pdf).
16. Ortho-McNeil-Janssen Pharmaceuticals. It's a good day to start getting your ADHD/ADD symptoms under control. Concerta, 2010 (http://www.concerta.net/ adult/adult-index.html).
17. Health.com. Advertiser opportunities. Health.com, 2011 (http://www.health.com/health/static/advertise-digital/online- advertisers.html).
18. Renki M. ADHD affects women differently: what to look for, how to fix it. Health, 2000 (http://www.health.com/health/condition-article/0,,20283301,00. html).
19. Connolly M. ADD women and girls: late diagnosis, little treatment. ADDitude Magazine 2010; August/September (http://www.additudemag.com/adhd/ article/1626.html).
20. Harris G, Carey B. Researchers fail to reveal full drug pay. New York Times 2008; 8 June.
21. Breggin P. Talking Back to Ritalin: What Doctors aren't Telling You about Stimulants and ADHD. Perseus Publishing, 2001.
22. Timimi S, Moncrieff J, Jureidini J, Leo J, Cohen D, Whitfield C, et al. A critique of the international consensus statement on ADHD. Clin Child Fam Psychol Rev 2004; 7: 59-63.
23. Timimi S. Naughty Boys: Anti-Social Behaviour, ADHD and the Role of Culture. Palgrave Macmillan, 2005.
24. Conners CK, Erhardt D, Sparrow E. Conners' (CAARS) Adult ADHD Rating Scales - Technical Manual. Multi-Health Systems, 1999.
25. Brown TE. Brown Attention-Deficit Disorder Scales (Manual). Psychological Corporation, 1996.
26. Kinsbourne M. Minimal brain dysfunction as a neurodevelopmental lag. Ann NY Acad Sci 1973; 205: 268-73.
27. Hill JC, Schoener EP. Age-dependent decline of attention deficit hyperactivity disorder. Am J Psychiatry 1996; 153: 1143-6.
28. Shaw P, Eckstrand K, Sharp W, Blumenthal J, Lerch JP, Greenstein D, et al. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proc Natl Acad Sci USA 2007; 104: 19649-54.
29. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 2006; 36: 159-65.
30. McGough JJ, Smalley SL, McCracken JT, Yang M, Del'Homme M, Lynn DE, et al. Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am J Psychiatry 2005; 162: 1621-7.
31. de Graaf R, Kessler RC, Fayyad J, ten Have M, Alonso J, Angermeyer M, et al. The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: results from the WHO World Mental Health Survey Initiative. Occup Environ Med 2008; 65: 835-42.
32. Fried R, Petty CR, Surman CB, Reimer B, Aleardi M, Martin JM, et al. Characterizing impaired driving in adults with attention-deficit/ hyperactivity disorder: a controlled study. J Clin Psychiatry 2006; 67: 567-74.
33. Biederman J, Petty C, Fried R, Fontanella J, Doyle AE, Seidman LJ, et al. Impact of psychometrically defined deficits of executive functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 2006; 163: 1730-8.
34. Asherson P, Adamou M, Bolea B, Muller U, Morua SD, Pitts M, et al. Is ADHD a valid diagnosis in adults? Yes. BMJ 2010; 340: c549.
35. Frodl T, Stauber J, Schaaff N, Koutsouleris N, Scheuerecker J, Ewers M, et al. Amygdala reduction in patients with ADHD compared with major depression and healthy volunteers. Acta Psychiatr Scand 2010; 121: 111-8.
36. Seidman LJ, Biederman J, Liang L, Valera EM, Monuteaux MC, Brown A, et al. Gray matter alterations in adults with attention-deficit/hyperactivity disorder identified by voxel based morphometry. Biol Psychiatry 2011; 69: 857-66.
37. Perlov E, Philipsen A, van Elst LT, Ebert D, Henning J, Maier S, et al. Hippocampus and amygdala morphology in adults with attention-deficit hyperactivity disorder. J Psychiatry Neurosci 2008; 33: 509-15.
38. Arnsten AF. Stimulants: therapeutic actions in ADHD. Neuropsychopharmacology 2006; 31: 2376-83.
39. Jensen PS, Arnold LE, Swanson JM, Vitiello B, Abikoff HB, Greenhill LL, et al. 3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry 2007; 46: 989-1002.
40. Koesters M, Becker T, Kilian R, Fegert JM,Weinmann S. Limits of metaanalysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol 2009; 23: 733-44.
41. Gualtieri CT, Ondrusek MG, Finley C. Attention deficit disorders in adults. Clin Neuropharmacol 1985; 8: 343-56.
42. Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemela A, Trott GE, et al. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attentiondeficit/ hyperactivity disorder. Biol Psychiatry 2008; 63: 981-9.
43. Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, et al. Efficacy and safety of OROS methylphenidate in adults with attentiondeficit/ hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol 2009; 29: 239-47.
44. Adler A, Spencer TJ, Levine LR, Ramsey JL, Tamura R, Kelsey D, et al. Functional outcomes in the treatment of adults with ADHD. J Atten Disord 2008; 11: 720-7.
45. Healy D. Shaping the intimate: influences on the experience of everyday nerves. Soc Stud Sci 2004; 34: 219-45.
46. Usher J. Women's Madness: Misogyny or Mental Illness? University of Massachusetts Press, 1991.
47. Sumnall HR,Woolfall K, Cole J, Mackridge A, McVeigh J. NICE guidance on ADHD: diversion and abuse of methylphenidate in light of new guidance. BMJ 2008; 337: a2287.
48. Government of Western Australia. Australian Secondary Students Alcohol and Drug Survey 2005, Summary of Western Australia Results (Report No. 37). Statistical Bulletin Number 37, Drug and Alcohol Office, Government of Western Australia, 2007.
49. Magomedov A. Adderal tips: how to convince your shrink you have ADHD/ADD. The Exiled, 2006 (http://exiledonline.com/adderall-tipshow-to-convince-your- shrink-you-have-addadhd/).
50. Gardner A. Some fake ADHD to get meds, special treatment. Medicinenet, 2010 (http://www.medicinenet.com/script/main/art.asp?articlekey=119239).
51. Schubert S, Hansen S, Dyer K, Rapley M. 'ADHD patient' or 'illicit drug user'? Managing medico-moral membership categories in drug dependence services. Discourse Society 2009; 20: 499-516.
52. Williams SJ, Martin P. Risks and benefits may turn out to be finely balanced. Nature 2009; 457: 532.
53. Westover AN, McBride S, Haley RW. Stroke in young adults who abuse amphetamines or cocaine: a population-based study of hospitalized patients. Arch Gen Psychiatry 2007; 64: 495-502.